Evidence map›Paper›PMID 31069155›Full record

ArticleOncoimmunology

Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.

Abdulla Watad, Dennis McGonagle, Nicola L Bragazzi, Shmuel Tiosano, Doron Comaneshter, Yehuda Shoenfeld, Arnon D Cohen, Howard Amital

Abstract read
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Cancer in connective tissue disease.Frontiers in immunology · 2025
    Review
  6. Article
  7. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.Clinical reviews in allergy & immunology · 2023
    Article
  8. Review
  9. Systemic Sclerosis Association with Malignancy.Clinical reviews in allergy & immunology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdulla WatadDepartment of Medicine 'B', The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.ORCID 0000-0002-1404-8027
Dennis McGonagleSection of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK.ORCID 0000-0001-7715-8226
Nicola L BragazziSchool of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.ORCID 0000-0001-8409-868X
Shmuel TiosanoDepartment of Medicine 'B', The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.ORCID 0000-0002-1748-4297
Doron ComaneshterChief Physician's Office, Clalit Health Services Tel Aviv, Tel-Aviv, Israel.
Yehuda ShoenfeldDepartment of Medicine 'B', The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.ORCID 0000-0003-2802-4090
Arnon D CohenChief Physician's Office, Clalit Health Services Tel Aviv, Tel-Aviv, Israel.ORCID 0000-0002-8377-9982
Howard AmitalDepartment of Medicine 'B', The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.ORCID 0000-0002-5406-7716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

autoantibodiesautoimmune diseasescancermalignancysclerodermaSystemic sclerosis

Identifiers

PMID31069155
PMCPMC6492983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.